Compare KOS & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KOS | MESO |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2011 | N/A |
| Metric | KOS | MESO |
|---|---|---|
| Price | $2.44 | $15.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $1.91 | N/A |
| AVG Volume (30 Days) | ★ 9.9M | 123.6K |
| Earning Date | 05-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,288,352,000.00 | N/A |
| Revenue This Year | $27.11 | $629.74 |
| Revenue Next Year | N/A | $30.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $10.17 |
| 52 Week High | $3.34 | $21.50 |
| Indicator | KOS | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 36.62 | 59.17 |
| Support Level | $2.33 | $13.71 |
| Resistance Level | $3.09 | $16.11 |
| Average True Range (ATR) | 0.16 | 0.49 |
| MACD | -0.06 | 0.09 |
| Stochastic Oscillator | 13.64 | 84.89 |
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.